中国医药生物技术
中國醫藥生物技術
중국의약생물기술
CHINESE MEDICINAL BIOTECHNOLOGY
2015年
4期
366-370
,共5页
郭健飞%牛桂芬%李健%任媛%白洁
郭健飛%牛桂芬%李健%任媛%白潔
곽건비%우계분%리건%임원%백길
阿尔茨海默病%糖尿病,2型%神经生长因子%二甲双胍
阿爾茨海默病%糖尿病,2型%神經生長因子%二甲雙胍
아이자해묵병%당뇨병,2형%신경생장인자%이갑쌍고
Alzheimer disease%Diabetes mellitus%type-2%Nerve growth factor%Metformin
目的 观察比较鼠神经生长因子(mNGF)及二甲双胍治疗 2型糖尿病相关阿尔茨海默病的疗效,初步探索 2型糖尿病相关阿尔茨海默病的治疗方法.方法 我院新诊断 2型糖尿病相关阿尔茨海默病 105例,分为 3组,每组 35例,分别给予二甲双胍联合胰岛素;mNGF联合胰岛素;二甲双胍、胰岛素联合 mNGF进行治疗.三组疗程均为 18周,每 6周随访一次;对治疗前后进行 MMSE、ADAS-cog、ADL评分比较.结果 二甲双胍联合胰岛素组患者 18周后 MMSE、ADAS-cog、ADL 评分无明显变化;mNGF 联合胰岛素、二甲双胍、胰岛素联合 mNGF组治疗 6周后在 MMSE、ADAS-cog、ADL评分较治疗前有改善(P < 0.05),18周后二甲双胍、胰岛素联合 mNGF组在 ADAS-cog和 ADL评分均较治疗前明显改善(P < 0.01).结论 mNGF能有效改善 2型糖尿病相关阿尔茨海默病患者的综合能力,而二甲双胍治疗并未看到明显效果.
目的 觀察比較鼠神經生長因子(mNGF)及二甲雙胍治療 2型糖尿病相關阿爾茨海默病的療效,初步探索 2型糖尿病相關阿爾茨海默病的治療方法.方法 我院新診斷 2型糖尿病相關阿爾茨海默病 105例,分為 3組,每組 35例,分彆給予二甲雙胍聯閤胰島素;mNGF聯閤胰島素;二甲雙胍、胰島素聯閤 mNGF進行治療.三組療程均為 18週,每 6週隨訪一次;對治療前後進行 MMSE、ADAS-cog、ADL評分比較.結果 二甲雙胍聯閤胰島素組患者 18週後 MMSE、ADAS-cog、ADL 評分無明顯變化;mNGF 聯閤胰島素、二甲雙胍、胰島素聯閤 mNGF組治療 6週後在 MMSE、ADAS-cog、ADL評分較治療前有改善(P < 0.05),18週後二甲雙胍、胰島素聯閤 mNGF組在 ADAS-cog和 ADL評分均較治療前明顯改善(P < 0.01).結論 mNGF能有效改善 2型糖尿病相關阿爾茨海默病患者的綜閤能力,而二甲雙胍治療併未看到明顯效果.
목적 관찰비교서신경생장인자(mNGF)급이갑쌍고치료 2형당뇨병상관아이자해묵병적료효,초보탐색 2형당뇨병상관아이자해묵병적치료방법.방법 아원신진단 2형당뇨병상관아이자해묵병 105례,분위 3조,매조 35례,분별급여이갑쌍고연합이도소;mNGF연합이도소;이갑쌍고、이도소연합 mNGF진행치료.삼조료정균위 18주,매 6주수방일차;대치료전후진행 MMSE、ADAS-cog、ADL평분비교.결과 이갑쌍고연합이도소조환자 18주후 MMSE、ADAS-cog、ADL 평분무명현변화;mNGF 연합이도소、이갑쌍고、이도소연합 mNGF조치료 6주후재 MMSE、ADAS-cog、ADL평분교치료전유개선(P < 0.05),18주후이갑쌍고、이도소연합 mNGF조재 ADAS-cog화 ADL평분균교치료전명현개선(P < 0.01).결론 mNGF능유효개선 2형당뇨병상관아이자해묵병환자적종합능력,이이갑쌍고치료병미간도명현효과.
Objective To observe and compare the therapeutic effect of mouse nerve growth factor (mNGF) and metformin, and evaluate the methods, in the treatment of Alzheimer's disease associated with type 2 diabetes. Methods 105 cases of Alzheimer's disease patients related to newly diagnosed type 2 diabetes in our hospital were classified into 3 groups. Patients in group 1 were given metformin in combination with insulin treatment, patients in group 2 were given mouse nerve growth factor combined with insulin group, and patients in group 3 were given metformin and insulin combined with mNGF. All the three groups were treated for 18 weeks, and followed up every 6 weeks with analysis of MMSE, ADAS-cog, ADL score before and after the treatment. Results The patients in group 1 after had no significant changes in MMSE, ADAS-cog, ADL score after 18 weeks treatment, while the patients in group 2 and 3 were significantly improved in MMSE, ADAS-cog, ADL score after 6 weeks treatment. Conclusion mNGF can effectively improve the comprehensive ability of AD associated with type 2 diabetes mellitus, and metformin treatment doesn't have obvious effect.